Subsidies versus intellectual property rights when innovators operate in two markets.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 27 01 2023
accepted: 10 04 2023
medline: 26 4 2023
pubmed: 24 4 2023
entrez: 24 04 2023
Statut: epublish

Résumé

Intellectual property rights are monopoly rights, which have undesirable welfare properties. Therefore, several studies suggest using rewards as incentives for innovation instead. However, these studies have thus far had little effect on actual policy, possibly because such rewards may be difficult to implement in practice. We suggest a new way of providing incentives to originators, which is easier to implement. Our suggestion can be used if there is an additional market in which originators operate, where copying is not easily possible. In this case, intellectual property rights in one market can be replaced by subsidies in the other market. Taking the music industry as example, copyrights in the records market could be replaced by subsidies in the market for live performances. We develop a partial equilibrium model that can be used to analyze in which cases the replacement of intellectual property rights in one market with subsidies in another market is welfare improving and better for the originator. A numerical application example suggests that the subsidy scheme may indeed be better in the music industry. The subsidy scheme can be implemented as a voluntary option, which would even be possible without changing the legal framework of intellectual property rights.

Identifiants

pubmed: 37093831
doi: 10.1371/journal.pone.0284880
pii: PONE-D-23-02377
pmc: PMC10124861
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0284880

Informations de copyright

Copyright: © 2023 Skliaustyte, Weber. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Health Policy. 2011 Oct;102(2-3):170-7
pubmed: 21724290

Auteurs

Egle Skliaustyte (E)

Center for Excellence in Finance and Economic Research, Bank of Lithuania, Vilnius, Lithuania.

Matthias Weber (M)

School of Finance, University of St. Gallen, St. Gallen, Switzerland.
Swiss Finance Institute, St. Gallen, Switzerland.

Articles similaires

Using Bayh-Dole Act March-In Rights to Lower US Drug Prices.

Lisa Larrimore Ouellette, Bhaven N Sampat
1.00
United States Cross-Sectional Studies Patents as Topic Humans Drugs, Generic
Conflict of Interest Japan Humans Drug Industry Retrospective Studies
Copyright Video Recording Blockchain Computer Security Humans
United States Humans Patents as Topic Biosimilar Pharmaceuticals Drug Industry

Classifications MeSH